(Press-News.org) ROCHESTER, Minn. -- Children who avoid situations they find scary are likely to have anxiety a Mayo Clinic study of more than 800 children ages 7 to 18 found. The study published this month in Behavior Therapy presents a new method of measuring avoidance behavior in young children.
The researchers developed two eight-question surveys: the Children's Avoidance Measure Parent Report and the Children's Avoidance Measure Self Report. The questionnaires ask details about children's avoidance tendencies, for instance, in addressing parents, "When your child is scared or worried about something, does he or she ask to do it later?" It also asks children to describe their passive avoidance habits. For example: "When I feel scared or worried about something, I try not to go near it."
One of the most surprising findings was that measuring avoidance could also predict children's development of anxiety. Children who participated in the study showed stable anxiety scores after a year had passed, but those who described avoidance behaviors at the onset tended to be more anxious a year later.
"This new approach may enable us to identify kids who are at risk for an anxiety disorder," says lead author Stephen Whiteside, Ph.D., a pediatric psychologist with the Mayo Clinic Children's Center. "And further, because cognitive behavior therapy focuses on decreasing avoidance behaviors, our approach may also provide a means to evaluate whether current treatment strategies work they we think they do."
In 25 anxious children surveyed following cognitive behavior therapy that slowly exposed children to the situations that caused fear, the avoidance scores from surveys of their parents declined by half. This likely indicates that part of the reason they're getting better is that they're no longer avoiding things, Dr. Whiteside says.
"Even after controlling for their baseline anxiety, those who avoided had more anxiety than kids who didn't avoid," Dr. Whiteside says. "That was consistent with the model of how anxiety disorders develop. Kids who avoid fearful situations don't have the opportunity to face their fears and don't learn that their fears are manageable."
Most children experience fears of one kind or another, but for some children those fears become heightened as part of an anxiety disorder. When children begin to avoid scary situations, anxiety disorders can become particularly disabling, preventing participation in everyday activities. Even though several methods exist to gauge children's fearful thinking and symptoms like feeling nervous, clinicians have had few tools until now to measure avoidance behaviors.
Dr. Whiteside is the developer of the Mayo Clinic Anxiety Coach, an iPhone app that helps individuals learn about anxiety, gauge and manage their symptoms, and make lists of activities to help them face their fears. The study was funded by Mayo Clinic Department of Psychiatry and Psychology.
###
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit http://www.mayoclinic.com and http://www.mayoclinic.org/news.
Journalists can become a member of the Mayo Clinic News Network for the latest health, science and research news and access to video, audio, text and graphic elements that can be downloaded or embedded.
http://www.mayoclinic.org/news2013-rst/7365.html
Children who avoid scary situations likelier to have anxiety, Mayo Clinic research finds
2013-03-12
ELSE PRESS RELEASES FROM THIS DATE:
Logging debris gives newly planted Douglas-fir forests a leg-up
2013-03-12
The downed limbs and other woody debris that are inevitable byproducts of timber harvest could be among the most important components of post-harvest landscapes, according to a new study led by the U.S. Forest Service's Pacific Northwest Research Station.
Researchers found that retaining moderate levels of logging debris, also known as "slash," helped to both directly and indirectly increase the growth rate of Douglas-fir seedlings replanted after harvest. The findings, which are among the first to speak to the benefits of second-growth logging debris, are published ...
Drug may improve outcomes after heart attack
2013-03-12
SAN FRANCISCO (March 10, 2013) — The prescription drug eplerenone appears to reduce the risk of cardiovascular mortality and heart failure after a heart attack by more than one-third, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The REMINDER (Reduction of heart failure morbidity in patients with acute ST-elevation myocardial infarction) trial was a randomized, double-blind trial of 1,012 patients who had a heart attack caused by a complete blockage of one of the heart's arteries. Patients had no signs or ...
Investigational drug reduces heart damage during angioplasty
2013-03-12
SAN FRANCISCO (March 10, 2013) — A single dose of an investigational anti-inflammatory drug, inclacumab, reduced damage to heart tissue during angioplasty in a study presented today at the American College of Cardiology's 62nd Annual Scientific Session.
More than 1 million coronary angioplasty procedures are performed in the United States each year, at a cost of more than $10 billion. Heart tissue can be damaged during angioplasty, often leading to additional procedures, poor outcomes and higher health care costs.
In this trial, researchers compared a single dose of ...
Clot-busting drug as effective as angioplasty
2013-03-12
SAN FRANCISCO (March 10, 2013) — A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
"Drug therapy before transfer is at least as effective as [angioplasty], and an urgent catheterization was avoided in two-thirds of patients," said Frans Van de Werf, MD, PhD, professor of cardiology at University of Leuven, Belgium, and the study's lead investigator.
"It gives [clinicians] time to consider other options, such ...
Drug reduces chest pain in patients with diabetes
2013-03-12
SAN FRANCISCO (March 10, 2013) — A commonly used anti-anginal drug reduces chest pain in patients with type 2 diabetes and appears to have a more pronounced effect in those with poorer glucose control, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Ranolazine is approved by the U.S. Food and Drug Administration for the treatment of chronic angina, or chest pain, both as first line therapy and as an add-on when symptoms are not relieved with other anti-anginal drugs, including beta-blockers, calcium channel ...
High-dose oral vitamins, minerals do not reduce recurrent cardiac events in heart attack patients
2013-03-12
SAN FRANCISCO (March 10, 2013) — Heart attack patients given a combination of high-dose oral vitamins and minerals do not exhibit a significant reduction in recurrent cardiac events, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. However, the results of one component of the NIH-funded Trial to Assess Chelation Therapy (TACT) study, shows that when combined with active chelation therapy, high-dose vitamins and minerals may provide some additional benefit.
The TACT study tested the safety and effectiveness of ...
Digoxin reduces hospital admissions in older patients with chronic heart failure
2013-03-12
SAN FRANCISCO (March 11, 2013) —Digoxin significantly reduces the likelihood of hospital admission due to all causes among ambulatory older patients with chronic heart failure and reduced ejection fraction (HFrEF), according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Researchers reviewed patient outcomes from 1995 in the Digitalis Investigation Group (DIG) trial of 6,800 patients with HFrEF—a condition in which the heart is too weak to pump and patients suffer from breathlessness and fatigue. Patients with HFrEF ...
Clot-busting drug benefits intermediate-risk patients with pulmonary embolism
2013-03-12
SAN FRANCISCO (March 11, 2013) — The clot-busting drug tenecteplase prevents death or circulatory collapse in a subgroup of patients with a blood clot in the lungs and appears to be especially useful in patients younger than 75, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Pulmonary embolism occurs when part of a blood clot in a vein breaks off and travels to the lungs. It is fatal about 10 percent of the time, killing between 60,000 and 100,000 Americans each year. The most common cause of death is progressive ...
Screenings, targeted care reduce heart failure in at-risk patients
2013-03-12
SAN FRANCISCO (March 11, 2013) — For at-risk patients, a simple screening and management program can be effective in preventing heart failure, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
The five-year STOP-HF study enrolled asymptomatic patients over 40 years of age with risk factors for heart failure and randomized them into an intervention and a control group. Patients in the intervention group were screened for blood levels of B-type natriuretic peptide (BNP), a hormone that indicates how well the heart ...
No benefit found from BP drug in treatment of recently hospitalized heart failure patients
2013-03-12
SAN FRANCISCO (March 11, 2013) —Despite high hopes that a blood pressure-lowering medication called aliskiren would help people following hospitalization for heart failure, no beneficial effects were found, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session.
Heart failure is the leading cause of hospitalization for people over age 65, costing Medicare billions of dollars annually, and researchers are always on the lookout for more effective treatments.
The Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT) ...